Neurocrine Biosciences | NBIX - Debt


Neurocrine Biosciences reported $439.1M in Debt for its fiscal quarter ending in June of 2025.





Debt Change Date
AbbVie USD 1000K 70.48B Sep/2025
Acadia Pharmaceuticals USD 56.29M 1.36M Jun/2025
Agios Pharmaceuticals USD 48.76M 47.62M Jun/2025
ALKERMES USD 72.68M 293.32M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 271.5M Jun/2025
Amgen USD 54.59B 1.62B Sep/2025
Biogen USD 6.29B 309.5M Sep/2025
BioMarin Pharmaceutical USD 603.87M 8.22M Jun/2025
Cytokinetics USD 858.06M 199.93M Jun/2025
Dynavax Technologies USD 285.5M 24.99M Jun/2025
Gilead Sciences USD 24.95B 6M Jun/2025
Halozyme Therapeutics USD 1.51B 1.65M Jun/2025
Incyte USD 42.41M 5.29M Jun/2025
Ionis Pharmaceuticals USD 1.23B 192.99M Sep/2025
Neurocrine Biosciences USD 439.1M 8.4M Jun/2025
Pfizer USD 60.85B 78M Sep/2025
Prothena USD 9.08M 699K Sep/2025
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Repligen USD 533.72M 149.97M Jun/2025
Sarepta Therapeutics USD 1.35B 215.59M Jun/2025
Teva Pharmaceutical Industries USD 17.07B 450M Sep/2025
Ultragenyx Pharmaceutical USD 36.3M 1.98M Jun/2025
Vertex Pharmaceuticals USD 1.53B 121.7M Jun/2025